Suite 2 Level 11, 385 Bourke Street, Melbourne VIC 3000 Prescient Therapeutics Limited T -+61 3 9692 7222| F-+61 3 9077 9233| W – ptxtherapeutics.com ABN 56 006 569 106 September 2026 Activities Report and Appendix 4C Highlights of the Quarter: • Phase 2a study of PTX-100 in cutaneous T-cell...
September 2026 Quarterly Update and Appendix 4C
Filed with ASX · · 8 pages · English
Release
Prescient Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Prescient Therapeutics
- PTX Successfully Completes $6m Raise Via SPP and Placement
- PTX-100 CTCL Phase 2a study reaches review milestone
- Prescient Therapeutics Opens SPP to Raise $7m Today
- Appendix 4E and 2026 Annual Report
- June 2026 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics